经匹配后放化疗与手术治疗局限期小细胞肺癌预后比较

doi:10.3760/cma.j.issn.1004-4221.2019.11.005

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的比较手术与放化疗治疗局限期小细胞肺癌(SCLC)患者的总生存(OS)、无进展生存(PFS)、颅内无进展生存(BMFS)预后差异。方法收集2000-2016年在浙江省肿瘤医院经手术治疗的局限期SCLC患者 69例,在 503例经根治性放化疗的局限期SCLC数据库中,按照T、N分期,治疗年份,年龄,性别,是否预防性脑照射(PCI)等进行1∶1匹配 69例患者为放化疗组。结果共纳入 138例患者,手术组 69例(Ⅰ期 24例、Ⅱ期 14例、Ⅲ期 31例),放化疗组 69例(Ⅰ期 24例、Ⅱ期 14例、Ⅲ期 31例)。手术组与放化疗组的中位OS期分别为37.1个月(95%CI为 24.1~50.2个月)和45.0个月(95%CI为 15.8~74.2个月),2、5年OS率分别为60%、45%和64%、45%(P=0.846);中位PFS期分别为27.1个月(95%CI为 0.00~60.3个月)和36.2个月(95%CI为 20.9~51.4个月),2、5年PFS率分别为52%、38%和56%、40%(P=0.610)。2、5年BMFS率分别为80%、76%和84%、80%(P=0.774)。Ⅰ期手术组、放疗组 5年OS率分别为62%、40%(P=0.038),PFS率分别为80%、40%(P=0.048),BMFS率分别为92%、95%(P=0.816)。Ⅱ期手术组、放化疗组 5年OS率分别为41%、51%(P=0.946),PFS率分别为65%、42%(P=0.280),BMFS率分别为75%、78%(P=0.720)。Ⅲ期手术组、放化疗组 5年OS率分别为25%、48%(P=0.220),5年PFS率分别为28%、36%(P=0.333),5年BMFS率分别为76%、74%(P=0.842)。结论手术治疗可为Ⅰ期患者带来生存获益,Ⅱ期患者两组生存相当,Ⅲ期患者放化疗组有更好生存趋势。最终结论需要更大样本或开展前瞻性研究得出。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈梦圆
	胡晓
	戚晓芳
	徐裕金
	董百强
	陈亚梅
	陈明

关键词 ：肺肿瘤/外科学, 肺肿瘤/放化疗法, 预后

Abstract：Objective To compare the overall survival (OS), progression-free survival (PFS) and brain metastasis free survival (BMFS) between the chemo-radiotherapy and surgical treatment for patients with limited stage small cell lung cancer (LS-SCLC). Methods Clinical data of 69 patients diagnosed with LS-SCLC undergoing surgery in Zhejiang Cancer Hospital between 2000 and 2016 were collected. According to T,N stage, treatment duration, age, gender and whether or not prophylactic cranial irradiation (PCI), 69 patients of 503 LS-SCLC patients who underwent standard radiochemotherapy were assigned into the radiochemotherapy group by using the pair-matched case-control method. Results Among 138 patients, 69 cases were allocated into the surgery group (24 cases of stage Ⅰ, 14 cases of stage Ⅱ and 31 cases of stage Ⅲ) and 69 cases in the radiochemotherapy group (24 cases of stage Ⅰ, 14 cases of stage Ⅱ and 31 cases of stage Ⅲ). The median OS time was 37.1 months (95%CI:24.1-50.2 months) in surgery group and 45.0 months (95%CI:15.8-74.2 months) in the radiochemotherapy group. The 2-and 5-year OS rates were 60% and 45% in the surgery group, and 64% and 45% in the radiochemotherapy group (P=0.846). The median PFS time was 27.1 months (95%CI:0.00-60.3 months) in the surgery group and 36.2 months (95%CI:20.9-51.4 months) in the radiochemotherapy group. The 2-and 5-year PFS rates were 52%,and 38% in the surgery group, and 56% and 40% in the chemo-radiotherapy group (P=0.610). The 2-and 5-year BMFS rates were 81% and 76% in the surgery group, and 84% and 80% in the radiochemotherapy group (P=0.774). The 5-year OS rate (62% vs. 40%,P=0.038) and 5-year PFS rate (80% vs.40%,P=0.048) for patients with stage Ⅰ LS-SCLC in the surgery group were significantly higher than those in the radiochemotherapy group. However, the 5-year BMFS rate in patients with stage Ⅰ LS-SCLC did not significantly differ between two groups (92% vs.95%, P=0.816). The 5-year OS rate (41% vs.51%, P=0.946), 5-year PFS rate (65% vs.42%, P=0.280) and 5-year BMFS rate (75% vs.78%, P=0.720) for stage Ⅱ SCLC did not significantly differ between two groups. As for stage Ⅲ SCLC patients, the OS rate (25% vs.48%, P=0.220), 5-year PFS rate (28% vs.36%, P=0.333) and 5-year BMFS rate (76% vs. 74%, P=0.84) did not significantly differ between two groups. Conclusions Surgical treatment can bring survival benefits to patients with stage Ⅰ LS-SCLC. The survival prognosis of stage Ⅱ patients is equivalent between two groups. Patients with stage Ⅲ LS-SCLC receiving radiochemotherapy obtain better survival trend compared with those undergoing surgery. The conclusion remains to be validated by studies with larger sample size or prospective investigations.

Key words： Lung neoplasm/surgery Lung neoplasm/radiochemotherapy Prognosis

收稿日期: 2018-08-07

基金资助:国家自然科学基金(81402540、81401911、81672972);国家卫生计生委科学研究基金—浙江省医药卫生重大科技计划(省部共建计划)项目(WKJ-ZJ-1701)

通讯作者: 陈明,Email:chenming@zjcc.org.cn

引用本文:

陈梦圆,胡晓,戚晓芳等. 经匹配后放化疗与手术治疗局限期小细胞肺癌预后比较[J]. 中华放射肿瘤学杂志, 2019, 28(11): 821-825.

Chen Mengyuan,Hu Xiao,Qi Xiaofang et al. Comparison of clinical prognosis of chemo-radiotherapy and surgical treatment for patients with limited stage small cell lung cancer after matching[J]. Chinese Journal of Radiation Oncology, 2019, 28(11): 821-825.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2019.11.005 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2019/V28/I11/821

[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J]. J Clin Oncol,2006,24(28):4539-4544. DOI:10.1200/JCO.2005.04.4859.
[2] Bayman NA,Sheikh H,Kularatne B,et al. Radiotherapy for small-cell lung cancer-where are we heading?[J]. Lung Cancer,2009,63(3):307-314. DOI:10.1016/j.lungcan.2008.06.013.
[3] National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology:small cell lung cancer (version 1.2016)[M]. Washington:NCCN,2016.
[4] Gong L,Wang QI,Zhao L,et.al. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery:is prophylactic cranial irradiation necessary for stage Ⅰ-Ⅲ disease?[J]. Int J Radiat Oncol Biol Phys,2013,85(1):196-200. DOI:10.1016/j.ijrobp.2012.03.038.
[5] American Cancer Society (ACS). Cancer facts & gures 2010[M]. Atlanta:ACS,2010.
[6] Tsuchiya R,Suzuki K,Ichinose Y,et al. Phase Ⅱ trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ-Ⅲ a small cell lung cancer:the Japan clinical oncology lung cancer study group trial (JCOG9101)[J]. J Thorac Cardiovasc Surg,2005,129(5):977-983. DOI:10.1016/j.jtcvs.2004.05.030.
[7] Shields TW,Higgins GA Jr,Matthews MJ,et al. Surgical resection in the management of small cell carcinoma of the lung[J]. J Thorac Cardiovasc Surg,1982,84(4):481-488.
[8] Chi-Fu JY,Derek Y,Paul J,et al. Role of adjuvant therapy in a population-based Cohort of patients with early-stage small-cell lung cancer[J]. J Clin Oncol,2016,34(10):1057-1064. DOI:10.1200/JCO.2015.63.8171.
[9] Bischof M,Debus J,Herfarth K,et al. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy[J]. Strahlenther Onkol,2007,183(12):679-684. DOI:10.1007/s00066-007-1740-z.
[10] Brock MV,Hooker CM,Syphard JE,et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy:its time has come[J]. J Thorac Cardiovasc Surg,2005,129(1):64-72. DOI:10.1016/j.jtcvs.2004.08.022.
[11] Shepherd FA,Ginsberg RJ,Feld R,et al. Surgical treatment for limited small-cell lung cancer[J]. J Thorac Cardiovasc Surg,1991,101(3):385-393.
[12] Fox W,Scadding JG. Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up[J]. Lancet,1973,2(1):63-65.
[13] Lad T,Piantadosi S,Thomas P,et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy[J]. Chest,1994,106(6):320S-323S.
[14] Eric L,Elizabeth B,Yoon KY,et al. The role of surgery in the treatment of limited disease small cell lung cancer time to reevaluate[J]. J Thorac Oncol,2008,3(11):1267-1271. DOI:10.1097/JTO.0b013e318189a860.
[15] Masayoshi I,Shinichiro M,Tsutomu Y,et al. Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System[J]. Ann Thorac Surg.2000,70(5):1615-1619.
[16] Andrzej B,Krzysztof K,Hanna KM,et al. A retrospective comparative study of surgery followed by chemotherapy vs.non-surgical management in limited-disease small cell lung cancer[J]. Eur J Cardiothorac Surg,2004,26(1):183-188. DOI:10.1016/j.ejcts.2004.04.012.
[17] Weksler B,Nason KS,Shende M,et al. Surgical resection should be considered for stage Ⅰ and Ⅱ small cell carcinoma of the lung[J]. Ann Thorac Surg,2012,94(3):889-893. DOI:10.1016/j.athoracsur.2012.01.015.
[18] Yu JB,Decker RH,Detterbeck FC,et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage Ⅰ small cell lung cancer[J]. J Thorac Oncol,2010,5(2):215-219. DOI:10.1097/JTO.0b013e3181cd3208.
[19] Schreiber D,Rineer J,Weedon J,et al. Survival outcomes with the use of surgery in limited stage small cell lung cancer:should its role be re-evaluated?[J]. Cancer,2010,116(5):1350-1357. DOI:10.1002/cncr.24853.